Next Century Growth Investors LLC Purchases 44,118 Shares of TransMedics Group, Inc. $TMDX

Next Century Growth Investors LLC grew its position in shares of TransMedics Group, Inc. (NASDAQ:TMDX) by 81.2% in the fourth quarter, according to its most recent filing with the SEC. The fund owned 98,468 shares of the company’s stock after acquiring an additional 44,118 shares during the quarter. Next Century Growth Investors LLC owned about 0.29% of TransMedics Group worth $11,979,000 at the end of the most recent reporting period.

A number of other hedge funds and other institutional investors have also recently modified their holdings of TMDX. Goldman Sachs Group Inc. boosted its position in shares of TransMedics Group by 50.1% during the 4th quarter. Goldman Sachs Group Inc. now owns 965,931 shares of the company’s stock valued at $117,506,000 after acquiring an additional 322,353 shares during the last quarter. Two Sigma Investments LP boosted its position in shares of TransMedics Group by 54.2% during the 3rd quarter. Two Sigma Investments LP now owns 635,394 shares of the company’s stock valued at $71,291,000 after acquiring an additional 223,409 shares during the last quarter. UBS AM A Distinct Business Unit of UBS Asset Management Americas LLC boosted its position in shares of TransMedics Group by 11.9% during the 3rd quarter. UBS AM A Distinct Business Unit of UBS Asset Management Americas LLC now owns 1,069,492 shares of the company’s stock valued at $119,997,000 after acquiring an additional 113,817 shares during the last quarter. Fred Alger Management LLC boosted its position in shares of TransMedics Group by 303.8% during the 3rd quarter. Fred Alger Management LLC now owns 150,741 shares of the company’s stock valued at $16,913,000 after acquiring an additional 113,408 shares during the last quarter. Finally, ArrowMark Colorado Holdings LLC boosted its position in shares of TransMedics Group by 54.0% during the 3rd quarter. ArrowMark Colorado Holdings LLC now owns 313,125 shares of the company’s stock valued at $35,133,000 after acquiring an additional 109,830 shares during the last quarter. 99.67% of the stock is currently owned by institutional investors.

Wall Street Analysts Forecast Growth

A number of research firms have recently commented on TMDX. TD Cowen lowered their target price on TransMedics Group from $190.00 to $120.00 and set a “buy” rating for the company in a research report on Wednesday, May 6th. UBS Group reiterated a “hold” rating on shares of TransMedics Group in a research report on Tuesday, May 26th. Wall Street Zen downgraded TransMedics Group from a “hold” rating to a “sell” rating in a research report on Saturday, May 9th. Canaccord Genuity Group lowered their target price on TransMedics Group from $152.00 to $124.00 and set a “buy” rating for the company in a research report on Wednesday, May 6th. Finally, Needham & Company LLC lowered their price target on TransMedics Group from $174.00 to $142.00 and set a “buy” rating for the company in a research report on Wednesday, May 6th. Six research analysts have rated the stock with a Buy rating and seven have assigned a Hold rating to the company. According to data from MarketBeat.com, the company presently has a consensus rating of “Hold” and an average target price of $134.00.

TransMedics Group Stock Down 0.9%

Shares of TMDX opened at $72.91 on Friday. The company has a market cap of $2.52 billion, a PE ratio of 16.57 and a beta of 1.91. The business has a fifty day moving average of $86.20 and a 200 day moving average of $115.18. TransMedics Group, Inc. has a 52-week low of $60.10 and a 52-week high of $156.00. The company has a quick ratio of 6.19, a current ratio of 6.74 and a debt-to-equity ratio of 1.70.

TransMedics Group (NASDAQ:TMDX) last issued its quarterly earnings results on Tuesday, May 5th. The company reported $0.30 earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of $0.62 by ($0.32). The company had revenue of $173.93 million during the quarter, compared to the consensus estimate of $174.44 million. TransMedics Group had a return on equity of 22.38% and a net margin of 27.04%.The firm’s quarterly revenue was up 21.2% compared to the same quarter last year. During the same quarter in the prior year, the business earned $0.70 earnings per share. On average, sell-side analysts expect that TransMedics Group, Inc. will post 1.98 EPS for the current year.

About TransMedics Group

TransMedics Group, Inc is a medical device company headquartered in Andover, Massachusetts, that specializes in advanced organ preservation and transport systems for transplantation. The company’s flagship technology, the Organ Care System (OCS), maintains donor organs in a near-physiologic, warm, beating state during transportation, with the aim of extending preservation times and improving post‐transplant outcomes. TransMedics’ solutions address a critical need in transplantation by reducing ischemic injury and expanding the donor organ pool.

TransMedics currently markets two commercially available OCS platforms.